Other Events ·
At its 2026 Annual Meeting of Stockholders on June 10, 2026, Palvella Therapeutics, Inc. stockholders approved an…
PVLAPalvella Therapeutics, Inc.
At its 2026 Annual Meeting of Stockholders on June 10, 2026, Palvella Therapeutics, Inc. stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the authorized shares issuable under the plan by 750,000 shares. Stockholders also elected George M. Jenkins, Todd C. Davis, and John Doux, M.D. as Class III directors, ratified Ernst & Young LLP as the independent auditor, and approved executive compensation on an advisory basis. The company operates in the biotechnology industry and develops therapeutic treatments.